Helsingborg, Sweden

Beryl Asp


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Beryl Asp: Innovator in Chemotherapeutic Advancements

Introduction

Beryl Asp is a notable inventor based in Helsingborg, Sweden. She has made significant contributions to the field of oncology through her innovative work on intravenous estramustine phosphate. Her research focuses on enhancing the therapeutic benefits of this anti-mitotic chemotherapeutic drug, which has proven efficacy against various types of cancer.

Latest Patents

Beryl Asp holds a patent for "Methods to potentiate intravenous estramustine phosphate." This invention describes methods that enhance the therapeutic benefits of intravenous estramustine phosphate, allowing for administration at high dosages exceeding 1300 mg as a single dose. The invention achieves efficacious enhancement of estramustine phosphate pharmacokinetics, making it a valuable option in cancer treatment. The formulation is applicable to a variety of cancers, including prostate, breast, lung, colorectal, pancreatic, ovarian, melanoma, and others.

Career Highlights

Beryl Asp is associated with Pharmacia Italia S.p.a., where she continues to contribute to advancements in cancer treatment. Her work has been instrumental in developing methods that improve the effectiveness of chemotherapeutic agents.

Collaborations

Beryl has collaborated with notable colleagues, including Michael S Kopreski and Bo Fredholm, to further her research and innovations in the field of oncology.

Conclusion

Beryl Asp's contributions to the field of cancer treatment through her innovative patent on intravenous estramustine phosphate highlight her role as a leading inventor in the medical community. Her work continues to pave the way for improved therapeutic strategies against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…